Samuel Frank

List of Publications by Year
in descending order

58 papers	2,159 citations	331670 21 h-index	223800 46 g-index
59 all docs	59 docs citations	59 times ranked	2381 citing authors

#	Article	IF	Citations
1	Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease. JAMA - Journal of the American Medical Association, 2016, 316, 40.	7.4	327
2	Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurology, 2017, 74, 977.	9.0	209
3	Treatment of Huntington's Disease. Neurotherapeutics, 2014, 11, 153-160.	4.4	163
4	Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurology, 2009, 9, 62.	1.8	133
5	Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Movement Disorders, 2018, 33, 282-288.	3.9	122
6	Cerebrospinal fluid tau, Aî², and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. Alzheimer's and Dementia, 2018, 14, 1159-1170.	0.8	96
7	Science and Ethics of Sham Surgery. Archives of Neurology, 2005, 62, 1357.	4.5	87
8	Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatric Disease and Treatment, 2010, 6, 657.	2.2	83
9	Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease. JAMA Neurology, 2021, 78, 312.	9.0	83
10	The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cognitive and Behavioral Neurology, 2004, 17, 201-7.	0.9	66
11	Common SNP-Based Haplotype Analysis of the 4p16.3 Huntington Disease Gene Region. American Journal of Human Genetics, 2012, 90, 434-444.	6.2	60
12	A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease. Clinical Neuropharmacology, 2008, 31, 127-133.	0.7	59
13	Advances in the Pharmacological Management of HuntingtonÊ¼s Disease. Drugs, 2010, 70, 561-571.	10.9	56
14	What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports. Neurology, 2005, 65, 1101-1103.	1.1	53
15	Ethics of sham surgery: Perspective of patients. Movement Disorders, 2008, 23, 63-68.	3.9	52
16	The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Movement Disorders, 2016, 31, 924-932.	3.9	48
17	Dystonia and Tremor. Neurology, 2021, 96, e563-e574.	1.1	46
18	Study of plasmaâ€derived miRNAs mimic differences in Huntington's disease brain. Movement Disorders, 2015, 30, 1961-1964.	3.9	36

#	Article	IF	Citations
19	Population stratification may bias analysis of PGC-1Î± as a modifier of age at Huntington disease motor onset. Human Genetics, 2012, 131, 1833-1840.	3.8	26
20	Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives. Tremor and Other Hyperkinetic Movements, 2014, 4, 224.	2.0	24
21	Clinical and Imaging Progression in the <scp>PARS</scp> Cohort: <scp>Longâ€Term</scp> Followâ€up. Movement Disorders, 2020, 35, 1550-1557.	3.9	23
22	Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception?. Journal of Medical Ethics, 2015, 41, 391-397.	1.8	22
23	Intermuscular coherence in amyotrophic lateral sclerosis: A preliminary assessment. Muscle and Nerve, 2017, 55, 862-868.	2.2	21
24	TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntingtonâ€™s disease. Biochemical and Biophysical Research Communications, 2012, 424, 404-408.	2.1	20
25	Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism and Related Disorders, 2019, 65, 178-183.	2.2	20
26	Sham surgery controls in Parkinson's disease clinical trials: Views of participants. Movement Disorders, 2012, 27, 1461-1465.	3.9	19
27	Utilization of Hospice Services in a Population of Patients With Huntington's Disease. Journal of Pain and Symptom Management, 2018, 55, 440-443.	1.2	15
28	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). Parkinsonism and Related Disorders, 2019, 62, 201-209.	2.2	15
29	Current Guidelines for Classifying and Diagnosing Cervical Dystonia: Empirical Evidence and Recommendations. Movement Disorders Clinical Practice, 2022, 9, 183-190.	1.5	15
30	Comparison of enrollees and decliners of Parkinson disease sham surgery trials. Movement Disorders, 2012, 27, 506-511.	3.9	14
31	Deutetrabenazine in the treatment of Huntington's disease. Neurodegenerative Disease Management, 2019, 9, 31-37.	2.2	14
32	Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study. PLOS Currents, 2011, 3, RRN1283.	1.4	14
33	HD-PRO-TRIADâ„¢ Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease. Tremor and Other Hyperkinetic Movements, 2014, 4, 223.	2.0	13
34	The Challenges of Residents Teaching Neurology. Neurologist, 2004, 10, 216-220.	0.7	10
35	Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntingtonâ€™s disease motor onset. Neurogenetics, 2013, 14, 173-179.	1.4	10
36	Medical errors on an inpatient neurology service. Neurology, 2003, 61, 254-257.	1.1	9

#	Article	IF	Citations
37	Patientâ€reported outcomes in Huntington's disease: Quality of life in neurological disorders (Neuroâ€QoL) and Huntington's disease healthâ€related quality of life (HDQLIFE) physical function measures. Movement Disorders, 2017, 32, 1096-1102.	3.9	9
38	Patient-reported outcome measures in Huntington disease: Quality of life in neurological disorders (Neuro-QoL) social functioning measures.. Psychological Assessment, 2018, 30, 450-458.	1.5	9
39	Trust in early phase research: therapeutic optimism and protective pessimism. Medicine, Health Care and Philosophy, 2008, 11, 393-401.	1.8	8
40	Meaning and purpose in Huntingtonâ€™s disease: a longitudinal study of its impact on quality of life. Annals of Clinical and Translational Neurology, 2021, 8, 1668-1679.	3.7	8
41	Long-term fetal cell transplant in Huntington disease: Stayin' alive. Neurology, 2007, 68, 2055-2056.	1.1	6
42	Epidemiology and Clinical Diagnosis of Parkinson Disease. PET Clinics, 2013, 8, 447-458.	3.0	6
43	Transportation innovation to aid Parkinson disease trial recruitment. Contemporary Clinical Trials Communications, 2019, 16, 100449.	1.1	6
44	New symptomatic therapies for Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 144, 199-207.	1.8	4
45	Mood fluctuations in Parkinson's disease: a pilot study comparing the effects of intravenous and oral levodopa administration. Neuropsychiatric Disease and Treatment, 2005, 1, 261-8.	2.2	4
46	Trauma-induced spinal vascular event producing hemipseudoathetosis. Movement Disorders, 2005, 20, 1378-1380.	3.9	3
47	Botulinum Toxin for Painful Spasms From Focal Seizures. Neurologist, 2013, 19, 15-16.	0.7	3
48	How different aspects of motor dysfunction influence dayâ€toâ€day function in huntington's disease. Movement Disorders, 2019, 34, 1910-1914.	3.9	3
49	Writing From the Wards. Neurologist, 2012, 18, 96-98.	0.7	2
50	Predictive modeling of spread in adultâ€onset isolated dystonia: Key properties and effect of tremor inclusion. European Journal of Neurology, 2021, 28, 3999-4009.	3.3	2
51	Financing graduate medical education. Nature Clinical Practice Neurology, 2009, 5, 58-59.	2.5	1
52	Managing chorea in Huntingtonâ€™s disease. Neurodegenerative Disease Management, 2011, 1, 295-306.	2.2	1
53	Reliability and Validity of the HD-PRO-TriadTM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2017, 6, 201-215.	1.9	1
54	Teaching residents to be teachers. Nature Clinical Practice Neurology, 2007, 3, 236-237.	2.5	0

#	Article	IF	Citations
55	P1â€026: CEREBROSPINAL FLUID TAU, AÎ², AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION. Alzheimer's and Dementia, 2018, 14, P275.	0.8	0
56	F08â€…Huntingtonâ€™s disease burden of illness (HDBOI): study methodology, sample representativeness and fieldwork risk mitigation strategy during the COVID-19 pandemic. , 2021, , .		0
57	F10â€…Development of assessments for later stage huntingtonâ€™s disease: HD structured interview of function and HD clinical status questionnaire. , 2021, , .		0
58	F07â€…Demographic characteristics and health resource use of the european participants from the huntingtonâ€™s disease burden of illness study (HDBOI). , 2021, , .		0